The value of AR-V7 in predicting therapeutic efficiency of abiraterone for CRPC patients

Q4 Medicine

中华泌尿外科杂志 Pub Date : 2020-03-15 DOI:10.3760/CMA.J.CN112330-20200109-00017

Shuo Wang, Peng Du, Yong Yang

{"title":"The value of AR-V7 in predicting therapeutic efficiency of abiraterone for CRPC patients","authors":"Shuo Wang, Peng Du, Yong Yang","doi":"10.3760/CMA.J.CN112330-20200109-00017","DOIUrl":null,"url":null,"abstract":"Objective \nDetermine the relationship between AR-V7 expression and treatment efficiency of abiraterone. \n \n \nMethods \nA prospective cohort study was conducted to detect CTCs AR-V7 in newly diagnosed CRPC patients, aged ≥18 years who were admitted to the urologic department of Peking University cancer hospital from January 2016 to January 2019, with one or more systemic metastases. All the patients intended to be treated with abiraterone. According to the AR-V7 status, patients were divided into 2 groups (AR-V7 positive and negative). PSA decline time, PSA PFS, clinical status PFS, imaging PFS and CSS are analyzed and compared by t-test and Chi-square between 2 groups. \n \n \nResult \n49 patients were AR-V7 negative and 28 were AR-V7 positive. Compared with AR-V7 positive patients, PSA decline time (72.04±66.92 vs. 190.11±102.44, P=0.000), PSA non-response rate (6.12% vs. 21.4%, P=0.040) are significantly lower in AR-V7 negative patients. PSA PFS(489.17±269.39 vs. 130.56±120, P=0.010), Clinical PFS (551.91±322.05 vs. 261.44±200.85, P=0.018), and Imaging PFS (523.7±223.28 vs. 247.56±202.80, P=0.003) are significantly longer in AR-V7 negative patients. \n \n \nConclusion \nExpression status of AR-V7 is related to the response of abiraterone treatment and the prognosis of the patients. \n \n \nKey words: \nProstatic neoplasms; Castration resistant prostate cancer; Androgen receptor splice variant 7(AR-V7); Abiraterone","PeriodicalId":10343,"journal":{"name":"中华泌尿外科杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华泌尿外科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN112330-20200109-00017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective Determine the relationship between AR-V7 expression and treatment efficiency of abiraterone. Methods A prospective cohort study was conducted to detect CTCs AR-V7 in newly diagnosed CRPC patients, aged ≥18 years who were admitted to the urologic department of Peking University cancer hospital from January 2016 to January 2019, with one or more systemic metastases. All the patients intended to be treated with abiraterone. According to the AR-V7 status, patients were divided into 2 groups (AR-V7 positive and negative). PSA decline time, PSA PFS, clinical status PFS, imaging PFS and CSS are analyzed and compared by t-test and Chi-square between 2 groups. Result 49 patients were AR-V7 negative and 28 were AR-V7 positive. Compared with AR-V7 positive patients, PSA decline time (72.04±66.92 vs. 190.11±102.44, P=0.000), PSA non-response rate (6.12% vs. 21.4%, P=0.040) are significantly lower in AR-V7 negative patients. PSA PFS(489.17±269.39 vs. 130.56±120, P=0.010), Clinical PFS (551.91±322.05 vs. 261.44±200.85, P=0.018), and Imaging PFS (523.7±223.28 vs. 247.56±202.80, P=0.003) are significantly longer in AR-V7 negative patients. Conclusion Expression status of AR-V7 is related to the response of abiraterone treatment and the prognosis of the patients. Key words: Prostatic neoplasms; Castration resistant prostate cancer; Androgen receptor splice variant 7(AR-V7); Abiraterone

查看原文本刊更多论文

AR-V7在预测阿比特龙治疗CRPC患者疗效中的价值

目的探讨AR-V7表达与阿比特龙治疗效果的关系。方法采用前瞻性队列研究，对2016年1月至2019年1月北京大学肿瘤医院泌尿外科收治的伴有一个或多个系统性转移的年龄≥18岁新诊断的CRPC患者进行ctc AR-V7检测。所有患者均打算用阿比特龙治疗。根据AR-V7状态将患者分为AR-V7阳性和AR-V7阴性两组。两组间PSA下降时间、PSA PFS、临床状态PFS、影像学PFS、CSS采用t检验和卡方分析比较。结果AR-V7阴性49例，阳性28例。与AR-V7阳性患者相比，AR-V7阴性患者PSA下降时间(72.04±66.92∶190.11±102.44,P=0.000)、PSA无缓解率(6.12%∶21.4%，P=0.040)均显著低于AR-V7阳性患者。AR-V7阴性患者PSA PFS(489.17±269.39比130.56±120,P=0.010)、临床PFS(551.91±322.05比261.44±200.85,P=0.018)、影像学PFS(523.7±223.28比247.56±202.80,P=0.003)均显著延长。结论AR-V7的表达状况与阿比特龙治疗的疗效及患者的预后有关。关键词:前列腺肿瘤;去势抵抗性前列腺癌;雄激素受体剪接变异7(AR-V7);Abiraterone

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华泌尿外科杂志 Medicine-Nephrology

CiteScore

0.10

自引率

0.00%

发文量

14180

期刊介绍： Chinese Journal of Urology (monthly) was founded in 1980. It is a publicly issued academic journal supervised by the China Association for Science and Technology and sponsored by the Chinese Medical Association. It mainly publishes original research papers, reviews and comments in this field. This journal mainly reports on the latest scientific research results and clinical diagnosis and treatment experience in the professional field of urology at home and abroad, as well as basic theoretical research results closely related to clinical practice. The journal has columns such as treatises, abstracts of treatises, experimental studies, case reports, experience exchanges, reviews, reviews, lectures, etc. Chinese Journal of Urology has been included in well-known databases such as Peking University Journal (Chinese Journal of Humanities and Social Sciences), CSCD Chinese Science Citation Database Source Journal (including extended version), and also included in American Chemical Abstracts (CA). The journal has been rated as a quality journal by the Association for Science and Technology and as an excellent journal by the Chinese Medical Association.